This study performed integrated morphological and molecular profiling, including whole-exome sequencing and RNA-Seq, on a multiinstitutional cohort of metastatic small renal masses (SRMs). The aim was to understand the molecular underpinnings of metastatic competence in these tumors, which are often managed with active surveillance. Researchers identified distinct genetic alterations in metastatic non-clear cell SRMs, such as NF2-altered tumors, ELOC-mutated RCC, and an mTOR-driven eosinophilic vacuolated tumor. Metastatic clear cell SRMs exhibited multi-hit aggressive genotypes, including recurrent losses of chromosomes 8p, 9, and 14q, along with co-occurring driver alterations in genes like BAP1 and mTOR pathway genes. Transcriptomic analyses revealed an enrichment of the NMF3 subtype, metabolic rewiring, and reduced cytotoxic immune effector function.
This study employed a multi-omics approach to decipher the metabolic-immune interplay in clear cell renal cell carcinoma (ccRCC). Researchers identified a five-gene metabolic signature (SUCLA2, ACAT1, PC, SUCLG1, HMGCS2) that predicts prognosis with superior accuracy compared to conventional clinical staging. This signature is associated with distinct tumor immune microenvironment states and enables patient stratification for personalized therapeutic strategies. In vitro experimental validations confirmed SUCLA2's role as a potential tumor suppressor, designating it as a promising target.
This study investigated the expression of SWI/SNF chromatin remodeling complex genes and its subtypes (cBAF, PBAF, GBAF) across 33 tumor types, utilizing DNA and mRNA data from The Cancer Genome Atlas (approximately 11,000 samples). Researchers found that the expression of certain genes like ACTL6B, DPF1, DPF3, and SMARCD3 varied most among tumor types, with 10 out of 33 tumor types exhibiting distinct expression signatures. While SWI/SNF gene mutations resulted in only minor changes in their own expression, they were linked to downstream regulation of transcriptional programs associated with epigenetic regulation, particularly in colon adenocarcinoma, kidney renal clear cell carcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma. These findings could contribute to the development of biomarkers and targeted therapies.
This study characterized the prevalence of KRAS G12C mutations in genitourinary malignancies, an area with limited data despite the approval of targeted therapies. Comprehensive genomic profiling was performed on over 13,000 samples of renal clear cell carcinomas, urothelial bladder carcinomas, and prostate acinar adenocarcinomas. Results indicated that KRAS G12C mutations are infrequent in these tumors, with an incidence of 0% in renal carcinomas, 0.6% in urothelial bladder carcinomas, and less than 0.01% in prostate adenocarcinomas. Despite their low frequency, these mutations represent an emerging therapeutic target, warranting further investigation, particularly in basket trials for patients harboring this actionable alteration.
This multi-omics bioinformatics study investigated the significance of TOP2A in renal cell carcinoma subtypes KIRC, KIRP, and KICH. Analyses revealed significant TOP2A overexpression associated with advanced pathological stages, high tumor grades, and poor patient outcomes. Genomic alterations, primarily amplifications and mutations, were identified at the TOP2A locus. The study suggests that TOP2A regulates the cell cycle, influences the immune microenvironment, and modulates key signaling pathways, positioning it as a prognostic biomarker and a potential therapeutic target.
The phase III COSMIC-313 study investigated the addition of cabozantinib to nivolumab and ipilimumab in previously untreated patients with advanced renal cell carcinoma. Final results confirmed a significant progression-free survival (PFS) benefit for the triplet regimen (16.6 months vs 11.2 months for the doublet). However, no significant improvement in overall survival (OS) was observed. Exploratory biomarker analyses suggest that patients with higher levels of M2-like macrophages might experience improved PFS and OS with the triplet therapy.